Six years after her first heart transplant, Tiernee’s body began to reject her donor heart and she developed end-stage kidney failure — her doctors knew they had to act quickly in order to save her life.
When Danny’s heart began to fail, his doctors implanted an LVAD to help improve blood flow. But when a clot formed in the pump six weeks later, his doctors chose to remove the LVAD and implant the SynCardia Total Artificial Heart. Read his story.
When Pat was admitted to Indiana University Health Methodist Hospital, he was facing a dire situation that had become all too familiar for his family. Read Pat’s story on his journey to finding a new heart.
Curious about how a SynCardia Total Artificial Heart is made? This overview gives you a sneak peek into our manufacturing process.
The SynCardia Total Artificial Heart is a life-saving treatment option for patients diagnosed with end-stage heart failure affecting both sides of the heart.
For children and adolescents diagnosed with end-stage congenital heart failure, there’s hope.
Thanks to the amazing team at Texas Children’s Hospital and the SynCardia Total Artificial Heart, 17-year-old Jordan was able to overcome end-stage congenital heart disease and receive a heart transplant. Read his amazing story here.
The SynCardia temporary Total Artificial Heart (TAH) allows for complete resection of the ventricles, including in patients who have cardiac tumors with ventricular involvement, providing long-term support until heart transplantation is possible.
Jaheim became the smallest and youngest patient to receive the SynCardia 50cc temporary Total Artificial Heart (TAH).
Learn more about mechanical circulatory support devices used to treat advanced and end-stage heart failure.
After 555 days of life with the SynCardia temporary Total Artificial Heart (TAH), Stan received his heart transplant.
After receiving the SynCardia temporary Total Artificial Heart, Tom was discharged home using the Freedom® Portable Driver.
For heart transplant recipients who experience graft failure, chronic allograft vasculopathy or rejection, the TAH overcomes limitations associated with the use of LVADs and BiVADs as a bridge to transplant in this population.
Heart failure is a chronic and progressive disease, but creating a plan with your medical team can help slow its advancement.
Right ventricular failure (RVF) is a serious and common complication in left ventricular assist device (LVAD) recipients that remains difficult to predict. A novel approach to patient consent may enhance your options in the operating room (OR) upon right ventricular (RV) visualization.